24.00p+1.50 (+6.67%)26 Feb 2024, 10:29
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Belluscura PLC Fundamentals

Company NameBelluscura PLCLast Updated2024-02-26
IndustryMedical DevicesSectorHealthcare
Shares in Issue164.153 mMarket Cap£39.40 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.07EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.0785Cash Equity Ratio0.1518
Quick Ratio4.1697Current Ratio8.89
Price To Book Value1.8556ROCE0

Belluscura PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Belluscura PLC Company Financials

Assets20222021
Tangible Assets$399,641.00$324,959.00
Intangible Assets$8.67 m$6.72 m
Investments00
Total Fixed Assets$9.07 m$7.05 m
Stocks$8.43 m$309,159.00
Debtors$4.01 m$2.54 m
Cash & Equivalents$2.04 m$15.89 m
Other Assets00
Total Assets$23.60 m$26.00 m
Liabilities20222021
Creditors within 1 year$3.05 m$1.08 m
Creditors after 1 year$200,432.00$247,823.00
Other Liabilities00
Total Liabilities$3.25 m$1.33 m
Net assets$20.35 m$24.67 m
Equity20222021
Called up share capital$1.66 m$1.55 m
Share Premium$33.54 m$26.19 m
Profit / Loss-$8.15 m-$5.21 m
Other Equity$20.35 m$24.67 m
Preference & Minorities00
Total Capital Employed$20.35 m$24.67 m
Ratios20222021
Debt Ratio$0.01$0.01
Debt-to-Equity$0.01$0.01
Assets / Equity1.07851.0785
Cash / Equity0.15180.1518
EPS-$0.06-$0.06
Cash Flow20222021
Cash from operating activities-$14.91 m-$6.99 m
Cashflow before financing-$7.62 m$18.37 m
Increase in Cash-$12.70 m$15.58 m
Income20222021
Turnover$1.40 m$420,316.00
Cost of sales$1.33 m$472,487.00
Gross Profit$68,105.00-$52,171.00
Operating Profit-$8.13 m-$5.19 m
Pre-Tax profit-$8.15 m-$5.21 m

Belluscura PLC Company Background

SectorHealthcare
ActivitiesBelluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
Latest Interim Date13 Sep 2023
Latest Fiscal Year End Date29 Jun 2023

Belluscura PLC Directors

AppointedNamePosition
2024-02-09Mr. Richard John PiperNon-Executive Director
2024-02-09Mr. Adam ReynoldsNon-Executive Director,Chairman
2023-10-03Mr. Anthony Stephen DyerExecutive Director,Chief Financial Officer and Company Secretary
2024-02-09Mr. David John PoutneyNon-Executive Director
2024-02-09Mr. Jonathan SatchellNon-Executive Director
2024-02-09Mr. Robert RaukerExecutive Director,Chief Executive Officer
2023-10-24Dr. Patrick John Strollo JrNon-Executive Director
2024-02-09Mr. Robert Sylvester FaryExecutive Director

Belluscura PLC Contact Details

Company NameBelluscura PLC
Address15 Fetter Lane, London, EC4A 1BW
Telephone+44 7814229686
Websitehttps://www.belluscura.com

Belluscura PLC Advisors